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HIGHLIGHTS 
 
 Globally adolescent males have poor knowledge of HPV and HPV vaccination.  
 Adolescent male knowledge of HPV is lower than their female peers. 
 High knowledge of HPV is not always predictive of HPV vaccine acceptance. 
 Standardised measures of HPV knowledge/acceptance used longitudinally are 
needed.  
 Imperative to identify methods of increasing male adolescent awareness of HPV.  
 
 
ABSTRACT 
Aim: To determine HPV and HPV vaccine awareness, knowledge and acceptance in male 
adolescents worldwide. 
Methods: A mixed methods systematic review was conducted. In accordance with PRISMA 
guidelines, relevant literature was identified through an electronic database search using 
specified keywords from inception to September 2015. Non-interventional studies presented 
in English that assessed HPV knowledge and provided data on male adolescents were 
included. If available, data on HPV and HPV vaccine perceptions, attitudes and/or HPV 
vaccine acceptance were also extracted. All studies were critically appraised to provide an 
indication of methodological quality. Results were compiled using a convergent synthesis.  
Results: 22 papers were included. The majority of studies were cross-sectional and 
conducted in the US and Europe. Across continents, regardless of a country’s HPV 
vaccination programme status, boys’ knowledge of HPV and/or HPV vaccination was 
generally low to moderate and significantly lower than female knowledge or awareness. 
There was a disagreement in the association of knowledge and vaccine acceptance, with 
higher knowledge not always being predictive of acceptance.  
Conclusions: Comparison and synthesis of research concerning HPV knowledge and 
attitudes was made difficult due to the lack of universal definition of vaccine acceptance, and 
no universally accepted tool for its measurement or for the measurement of HPV knowledge. 
It is imperative that future research utilises consistent measures of HPV knowledge and 
attitudes to facilitate interpretation and comparison across studies internationally. 
Prospective longitudinal studies would be more informative providing data on factors that 
influenced the move from vaccine intention to uptake.  
 
 
KEYWORDS 
HPV; Human papillomavirus; Systematic review; adolescents; men’s health; cancer; cancer 
prevention; vaccination  
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INTRODUCTION  
Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide 
[1]. HPV infection is well-recognised as the causative agent in all cervical cancers; with two 
types (16/18) underpinning 70% of cervical cancer cases worldwide [2]. HPV is also linked to 
genital, anal [3], and oropharyngeal cancer (OPC) [4]. Approximately 95% of anal cancers 
are caused by HPV; 65% of vaginal cancers; 50% of vulvar cancers, and 35% of penile 
cancers [5]. OPC shows a regional/socio-economic variation; in comparison to the high-
income areas of North America, Northern and Western Europe, Australia and Japan with a 
prevalence range of 39-56%, the rest of the world appears to have a lower prevalence (13-
38%) [6]. In the United States (US), it is predicted that the number of HPV-related OPCs 
diagnosed per year will soon surpass the annual number of cervical cancer cases [7]. 
Infection with low-risk HPV (6/11) are also implicated in the development of genital warts [8]. 
 
Despite the impact of HPV on both sexes, few countries have implemented a vaccination 
programme for both adolescent boys and girls. Australia was the first country to initiate 
government-funded universal HPV vaccination, and began including boys in a national 
school-based HPV vaccination program in February 2013 [9].  The US also recommends 
universal vaccination, with the Vaccines for Children (VFC) Program funding HPV 
vaccination for children aged 9–18 years who are uninsured or underinsured [10]. The UK 
national school-based programme provides coverage for girls only as is the case in most 
European countries [11], with the exception of Austria who, in 2014, were the first in Europe 
to commence a publicly funded universal programme [12]. Switzerland recommend 
vaccination for boys and men aged 11 – 26 [13]. Within country, HPV vaccination for boys is 
recommended in Saxony (Germany) and Emilia-Romagna/Sicily (Italy). In Canada, of the 
thirteen provinces and territories, only Prince Edward Island, Alberta and Nova Scotia 
include boys in their school-based programme [14-17], although the provinces of Manitoba 
and Quebec may soon follow suit [18-19]. 
 
There is substantial debate around the inclusion of males in HPV vaccination programmes 
[20-21]. Many countries do not include men, and focus on achieving a high coverage in 
females to promote herd protection, i.e. a reduction in the risk of infection in males due to 
reduced exposure as a result of female vaccination. There is some emerging evidence that 
female only vaccination programmes with high female vaccination rates resulted in a one 
third reduction in the number of boys with genital warts [22]. The incremental benefit of 
extending the vaccine to males is believed to be dependent on coverage in females. With a 
low uptake in girls, the benefit of vaccinating boys is easily demonstrated; but when more 
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than 70% of females are vaccinated, the gender neutral vaccine approach appears less 
effective [23].   
 
However, a female only vaccination strategy leaves a number of men vulnerable to HPV 
infection, and unvaccinated males are not protected if they move outside of the herd (due to 
migration or travel) and have sex with an unvaccinated partner. Additionally, this approach 
will have minimal effect on men-who-have-sex-with-men (MSM). In the UK, the Joint 
Committee on Vaccination and Immunisation (JCVI), while recognising the merits of 
universal gender-neutral vaccination, has recently released a recommendation that MSM 
under age 45 who attend Genito-Urinary Medicine (GUM) or HIV clinics should be offered 
vaccination [24]. Similarly, British Columbia (Canada) offers HPV vaccination for free to girls 
and “at-risk” boys (such as boys who are homeless or gay). This approach may have limited 
efficacy in preventing HPV-related disease, as a significant number of MSM may already 
have had sexual intercourse before presentation at GUM/HIV clinics [25]. In addition, for the 
HPV vaccine to be most effective, it should be given at a younger age (9-15 years), before 
exposure to HPV through sexual contact and when immunogenicity is at its most effective 
[26]. It is likely that the most effective, practical and ethical solution is to offer HPV 
vaccination to both adolescent males and females. There is also mounting evidence that 
universal vaccination is cost effective [27] particularly when the costs associated with 
oropharyngeal cancer [28] and genital warts treatment [29] are considered. A wider socio-
economic perspective further supports this evidence, with increased benefit to society 
characterised through improved productivity, increased earnings and enhanced tax revenue 
due to vaccine related reductions in mortality and morbidity [30].  
 
As countries are increasingly recommending and funding HPV vaccination for males, it is 
imperative to better understand the knowledge, awareness and attitudes of adolescent boys 
to HPV and HPV vaccination, in order to ensure uptake is maximised and both boys and 
girls are protected against HPV-related cancers in the future. The aim of this review was to 
determine the level of HPV and HPV vaccine knowledge and vaccine acceptance in male 
adolescents worldwide. 
 
METHODS  
A mixed methods systematic review including both quantitative and qualitative data was 
conducted.  
 
Search strategy 
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In accordance with PRISMA guidelines, relevant literature was identified through an 
electronic database search of Medline (1966 – December 2015), CINAHL (1982 – December 
2015), PsychINFO (1872 – December 2015), PsychARTICLES, Web of Science. Keywords 
to identify research into HPV knowledge and attitudes were taken from a previous 
publication focussed on men-who-have-sex-with-men (MSM) [31], and combined with search 
terms for male adolescents. Keywords used therefore were: (Human Papillomavirus OR 
HPV) AND (accept* OR aware* OR attitude* OR barrier * OR belie* OR behav* OR benefit* 
OR comprehend* OR communicat* OR cognit* OR cue OR decision OR educat* OR 
experience OR intent* OR know* OR motivat* OR norm* OR percep* OR perceive* OR 
prefer* OR psycholog* OR psychosocial OR represent* OR risk* OR side effect* OR subject* 
OR understand* OR will*) AND (male OR boy OR son) AND (adolescent* OR child*). The 
reference list of each relevant study was searched for additional relevant papers.  
 
Eligibility criteria 
Non-interventional studies presented in English that assessed HPV knowledge and provided 
data on male adolescents i.e. have you heard of HPV? and/or have you heard of HPV 
vaccine? were included. If available, data on HPV and HPV vaccine perceptions, attitudes 
and/or HPV vaccine acceptance were also extracted. An adolescent was operationalised in 
accordance with the WHO definition, which defines adolescence as after childhood, but 
before adulthood with an age range of 9 – 19, although for this review, the upper age limit 
was extended to 20 years, as many European secondary schools have an upper age limit of 
20 years old [32]. Studies solely investigating the prevalence of HPV, studies not specific to 
HPV vaccination (i.e. general vaccination attitudes), those focused on parent or health care 
provider opinion on vaccination of adolescent males, and those including an 
immunosuppressed children or a HIV population were excluded. Reviews, editorials, 
comments and conference presentations were also excluded.  
 
Study selection 
Following completion of the database searching, and removal of duplicates, titles were 
divided between 2 reviewers (GP and RM). Studies were selected based on the 
inclusion/exclusion criteria. Any titles that lead to uncertainty were retained for abstract 
screening. Abstract and full-text screening was conducted by one reviewer (GP), any 
ambiguity in terms of study selection and the rationale for inclusion of the final studies were 
discussed with the review team. 
 
Study quality 
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As per Patel et al. [32], to provide an indication of the quality of the included studies, all 
quantitative papers were assessed using a checklist created using the Centre for Evidence-
Based Medicine (CEBM) tool for appraising survey studies and the guidance provided by 
Pettigrew and Roberts [33]. The Critical Appraisal Skills Programme tool was used to 
appraise the qualitative studies [34]. These two tools have been used previously in a review 
of adolescent HPV knowledge in Europe [32]. Two reviewers (RM and GP) completed the 
checklists for each included study, a third reviewer OS appraised those studies where the 
quality/fulfilment of criteria could not be agreed between the two main reviewers. 
 
Data synthesis 
Results of this systematic mixed studies review were compiled using a convergent synthesis  
[35]. A convergent synthesis involves initially synthesising qualitative and quantitative 
separately, then integrating the qualitative and quantitative summaries.  
 
RESULTS  
As can be seen from Figure 1, 113 studies met the initial inclusion criteria. On full text 
review, 91 were excluded as they did not focus on HPV specifically (n = 6), did not include 
adolescents (n = 71), had no separate male adolescent data (n = 7) or did not assess 
knowledge of HPV or HPV vaccination (n = 7). Twenty-two relevant publications were 
included and are summarised in Table 1. As can be seen from Table 1, three studies consist 
of the same sample and methodology, but report on different analysis [37,38,41]; 
consequently 20 studies have resulted in 22 separate publications. All studies were cross-
sectional, with the majority (n = 17) using a self-administered questionnaire to assess HPV 
knowledge. Two studies used mixed methods [40,52] and one was solely qualitative [43]. 
Sample sizes ranged from 20 [57] to 2500 [52]. Participants were largely recruited from 
schools (n = 13), but online recruitment (n = 2), health centres (n = 1), or community sources 
(n = 4), were also used. There was wide representation from across the globe, although 
most of the included studies were conducted in the US (n = 5), Western Europe (n = 7) or 
Australia (n = 2). Nevertheless, one study was conducted in Africa [57], one in Hungary [48], 
one in Romania [42] and three in Asia [52-54].  
 
Study quality  
The methodological quality of the reviewed studies was generally acceptable, with the 
majority of studies (n = 17) being considered to be of moderate to high quality (see Table 2 
and 3). The majority of quantitative/mixed method studies studies achieved a satisfactory 
response rate (59-100%) (n = 15), with only Samkange-Zeeb [44] not attaining a satisfactory 
level, although many did not base their sample size on a pre-study consideration of 
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statistical power (n = 14). The method of recruitment used by a number of studies lead to 
difficulty in generalising findings, as a large number of the included studies used a 
convenience sample, and only a few studies recruited in a way whereby the study sample 
could be considered representative of the population (n = 7). All studies were cross-sectional 
which prevents any statements to be made regarding causality.  
 
HPV knowledge 
All 20 studies either assessed knowledge of HPV or knowledge of HPV vaccination.  
 
Of the 19 quantitative studies, 18 assessed awareness and/or knowledge of HPV (all except 
[36]), with varying methods of measurement. Eleven studies assessed awareness by asking 
an initial question ‘Have you heard/are you aware of HPV?’ [37,38,40-42,44,46-49,50,51,56]; 
this was followed by combinations of various HPV knowledge questions, largely focussed on 
what diseases are caused by HPV (different cancers types/genital warts), mode of HPV 
transmission, who can be affected by HPV, and how to protect against HPV. The remaining 
7 studies also assessed knowledge in a variety of ways, from asking a broad question on 
‘What is HPV’’/”What do you know about HPV?” with multiple-choice response options 
[45,54], or ‘Is genital/cervical cancer caused by HPV?” [39,52], or “Have you ever discussed 
HPV with friends?” [55] Qualitatively, Hilton et al. [43] assessed HPV knowledge via 
discussions on awareness of disease, and understanding of disease process and symptoms.  
 
Sixteen studies assessed awareness and/or knowledge of HPV vaccination 
[36,37,39,40,42,44,46-50,52-56). Similar to HPV knowledge, 11 studies assessed 
awareness initially with a question on ‘Have you heard of/are you aware of the HPV 
vaccine?’ [36,37,39,40,42,44,48,49,50,52,53]. Moss et al [37] was the sole study to ask 
directly if respondents were aware that boys could receive the HPV vaccine. In two of these 
studies, the initial awareness question was followed by various other vaccine knowledge 
questions such as ‘Can you get HPV by getting the vaccine?’, ‘Will the vaccine protect 
against other STIs?’, ‘When should the vaccine be given?’ [40,49]. The remaining five 
studies did not include an initial awareness question, but assessed vaccine knowledge in a 
variety of ways including indicating yes/no to the statement ‘The vaccine won’t work if you 
are sexually active’ [54-56], and asking participants to indicate from a list of answers ‘What 
diseases are protected by the vaccine?’ [54].  
 
Across continents, regardless of a country’s HPV vaccination programme status, boys’ 
knowledge of HPV and/or HPV vaccination was generally low to moderate (5 – 65% had 
heard of HPV; 1 – 45% had heard of HPV vaccination)(Figure 2), and significantly lower than 
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female knowledge or awareness where it was compared [36,42,44,47,48,49,56], or at a 
similar level to the level of knowledge of unvaccinated females [45, 56]. Low knowledge in 
boys was also demonstrated in the qualitative study, where boys showed little knowledge of 
HPV, believing that it only affected female [43]. This is with the exception of three studies 
where knowledge in both genders was so low that no gender difference was noted 
[42,50,57]. Contrary to this, in two studies male adolescent knowledge was high including a 
study of adolescent males in Thailand [54] and a recent study of MSM aged 16-20 years in 
Australia [55]. Interestingly, Songthap et al. [54] found that boys had high knowledge that 
was comparable to females, but that most boys disagreed that ‘HPV infection in men was as 
important as in women’ [54].  
 
Only studies in the US were conducted at a time when vaccination was available in country 
for adolescent males (since 2009), but despite this, low to moderate knowledge was still 
recorded (Figure 2) [36,37-41]. For example, a high quality, nationally representative sample 
survey found that only 25% of boys aged 11 – 17 years old were aware of HPV and 26% 
were aware of an HPV vaccine. Of those that were aware of the HPV vaccine, only 38% 
were aware that a vaccine was available for boys (approximately 10% of the overall sample) 
[37]. However, in a secondary analysis that examined the older 15 – 17 year old subsample 
[41], the percentage of adolescents who reported knowledge of HPV (not HPV vaccination) 
increased significantly from 25% to 40% (p = 0.0003) [41] indicating that age may influence 
HPV knowledge. (The study focussed on sexual disinhibition, so these items were not asked 
of younger boys). Indeed in other studies with higher male knowledge, the sample included 
participants over the age of 19 [47,49] which may have elevated the level of the sample’s 
knowledge. This increased knowledge was also reported in another high quality US study 
that found adolescents over the age of 15 were more likely to report HPV vaccine awareness 
[36], although this study did not examine HPV knowledge. Contrarily, an older age group did 
not explain the high level of knowledge recorded in a high quality study of 12 – 15 year old 
Thai students [54]  
 
It is also possible that it may not be age, but sexual activity that influences adolescent 
knowledge. Sexual orientation seems to impact on level of knowledge, with adolescent MSM 
having higher knowledge [40,55] although both of these studies are limited by their 
methodological quality. In Australia, in a study of 200 adolescent (16-20 years) MSM, there 
was a high level of knowledge, despite male vaccination not being routinely offered at the 
time of data collection [55]. In a study of urban, low income adolescents in the USA, 
conducted after the introduction of universal HPV vaccination, a high proportion (77%) of the 
42% of males who had heard of HPV were MSM, although it should also be noted that the 
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mean age of MSM was 18 years old compared to the mean age of the heterosexual 
adolescents of 16 years [40]. It is possible that those who are identifying as MSM are older 
and therefore more sexually active (which may increase awareness). In addition, MSM may 
also have more frequent exposure to STI messages, more health discussions with their 
physician, and more experience of taking control of their sexual health. This possible 
association between age and/or sexual activity was also seen in a US study of inner city 
Caribbean and African American adolescents [39]. This study reported high levels of HPV 
knowledge in 13 – 19 years old; however, this is confounded by half of the sample being 18 
or 19 years old, and 70% reporting sexual activity (98.6% with the opposite sex) [39]. It is 
important to note that this study was assessed as low quality and that HPV vaccines were 
administered to boys whose parents reported positive interest in receiving this immunization, 
which was done during the same clinic visit [39] and this may have impacted on outcome. 
This also occurred in the Australian MSM study, whereby the participating adolescent males 
were involved in another HPV infection study that offered free HPV vaccination at the end of 
the study [55].  
 
As all studies were cross-sectional, it was not possible to determine if time (i.e. allowing HPV 
vaccination programmes to become more established) impacts level of knowledge.  
 
HPV vaccine attitudes and acceptance 
Association of HPV vaccine acceptance and HPV knowledge 
Thirteen studies examined HPV vaccine acceptance [36-39,40,42,46,48,49,51,52,54,55,57], 
which was expressed as the percentage of adolescent boys who would be willing to be 
vaccinated against HPV. In the US (where vaccination was available for adolescent boys) 
the range for willingness to be vaccination was 30 [38] – 65% [39], one study reported actual 
vaccine uptake of 11.5% [36]. In Europe the range was 40% [49] – 75% [51]; Asia 25% [54] 
– 30% [52]; Australia 86% (MSM sample) [55], in Africa 100% willingness was reported [57].  
There was a general association between level of knowledge and vaccine acceptability, with 
higher knowledge being associated with greater acceptability [39,40,42,46,49,55], although 
this data was generated from studies rated low to medium quality. For example, in the UK, 
boys who were unsure whether to have the vaccine they were significantly less likely to have 
heard of HPV (44%) compared with boys who intended (63%) (X2(1) = 9.35, p = 0.002) or 
did not intend (58%) to receive the HPV vaccine (X2(1) = 6.46, p = 0.01) [46]. Similarly, in the 
US, knowledge was associated with willingness to be vaccinated, with 65% of the 
adolescent boys who knew about HPV (i.e. that HPV is associated with genital cancer) being 
significantly associated with interest in receiving HPV vaccination [39]. However, as 
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previously stated, this was rated a low quality study, as vaccination was offered at end of 
study and this may have recruited participants more accepting of vaccination.  
Notably, some studies (of medium to high quality) did not find a positive association between 
HPV knowledge and willingness to be vaccinated. For example, in a high quality US study 
conducted on a representative sample of adolescent boys from a rural location, 40% knew 
about HPV vaccination, but only 1.4% had received the full three doses of vaccine [36]. It 
should be noted that the adolescents in this study were not asked specifically if they knew 
the vaccine was available for boys, so they might have been only aware of female 
vaccination. This was also demonstrated in another high quality US study conducted on a 
nationally representative sample, where only 10% of male adolescents were aware of the 
existence of an HPV vaccine for boys specifically, while 26% were aware of the HPV vaccine 
in general [37]. This study also does not support the hypothesis that acceptance and 
knowledge are positively correlated, as despite low knowledge of HPV (10% of sample), 
almost 30% were willing to be vaccinated [37]. Similarly, in another high quality study 
conducted in Hungary, despite low knowledge in both primary and secondary school boys 
(20% and 29% respectively knew what HPV was), 60% of boys would request the vaccine if 
it was free [48]. Likewise in Mali, in a small study conducted prior to the introduction of an 
HPV vaccination programme, 100% of a convenience sample of adolescents (n = 20) aged 
12 – 17 years, said they would be willing to be vaccinated, despite very low knowledge in 
both males and females [57]. A similar pattern was seen in another high quality study in 
Sweden [51] where despite low knowledge, 74% of 15-16 year old boys indicated they would 
like to be vaccinated.  
 
Attitudes and HPV vaccine acceptance  
The majority of studies also examined factors associated with acceptance [37-41,43,48-
52,54,55,57]. Reasons for non-acceptance of vaccination were based around current sexual 
inactivity [42,46,51], regular condom use [39], or regular physical health examinations [39] 
and so the perceived risk of acquiring HPV was low. Those boys who had a high perceived 
likelihood of becoming infected [37], either from having a high number of sexual partners 
[39], previous STIs [39], or partaking in risky sexual behaviour [40] had a higher acceptance 
of vaccination. In addition, in a Swedish study, knowledge that the vaccine also protected 
against genital warts increased acceptance [51], which may indicate that the participants 
were more concerned or perceived themselves at greater risk of contracting genital warts.  
 
Other reasons for vaccine acceptance were focused on severity, i.e. the perception that  
contracting HPV would have serious implications (largely around the fear of disease and risk 
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of developing cancer) [40,46,50,52], or regret if they later became infected with HPV [37], 
and wanting to protect future partners [37]. As noted earlier, it is important to differentiate 
between willingness to be vaccinated and actual receipt of vaccination, for example, and 
intention to receive the vaccine. In Sweden, 74% of boys aged 15 – 20 years indicated they 
would like to be vaccinated, but crucially only 4% had the intention of getting vaccinated in 
the future [50]. 
 
In addition to perceived low risk, other reasons boys expressed for not wanting to receive an 
HPV vaccine were regarding cost (price was too high) [48,55,57], and generic vaccination 
concerns such as worries about side effects [37,40,48,52], vaccine safety [54], fear of 
needles [43,48], or pain [37,42,43]. In India, low vaccine acceptance was also linked to 
recent media coverage of vaccine-related deaths [52].  
 
DISCUSSION  
In recent years, there has been an increase in studies examining knowledge and awareness 
of HPV in adolescent boys. This is likely reflective of changes in policies in an increasing 
number of countries worldwide to recommend a gender-neutral vaccine strategy. The 
majority of studies have been cross-sectional and conducted in the US and Europe; 
however, a small number of Asian and African countries have also examined the issue. This 
reflects  a fundamental gap in knowledge and research on HPV and its implications given 
that low middle income countries (LMICs) report much higher prevalence of HPV (e.g. 33% 
in sub-Saharan Africa) [58], with all viral infections (including infection with HPV) leading to 
one fifth of cancer deaths in LMICs [59]. In addition, LMICs bear most of the burden of the 
global HIV epidemic [60]. The higher level of co-infection with HPV in those positive for HIV 
in the African population for example, increases associated cancer risk.   
 
As can be noted from this systematic review, comparison and synthesis of research 
concerning HPV knowledge and attitudes is made more difficult to interpret as there is 
currently no universal definition of vaccine acceptance, and no universally accepted tool for 
its measurement or for the measurement of HPV knowledge. The included studies assessed 
knowledge differently, posing different questions to participants, for example, ‘Have you ever 
heard of HPV?’ or ‘Which virus causes cervical cancer?’. However, regardless of question 
asked, it is important to note that adolescent male knowledge was statistically lower than 
their female counterparts. There appears to be a tiered level of knowledge and it is important 
to be able to distinguish between being aware of HPV; being aware that there are HPV 
vaccines; and knowing the vaccines are available for boys, which was highlighted in the 
nationally represented study of US adolescents [37]. This inconsistency between studies 
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makes comparison problematic, as the outcome of interest is measured in various ways, 
making it difficult to draw conclusions and recommendations and to develop methods to 
enhance vaccine acceptance. 
 
In general, adolescent boys’ knowledge of HPV was below that of female adolescents 
though there were exceptions to this, with two studies suggesting that female and male 
adolescent knowledge was so low no gender difference was detected [50,57], and a study of 
male adolescents in Thailand whose knowledge was as high as that of the female 
adolescents [54]. It was difficult in certain studies to separate the adolescent outcome from 
the young adult [39,44,47,49,52,55] and it is possible that the age of the sample and sexual 
experience could be contributing to the variability in knowledge reported. There is an 
indication that knowledge may increase with increasing age and sexual experience. We 
know that the HPV vaccine is most effective if given before commencement of sexual activity 
and hence possible exposure to HPV [61], therefore efforts to enhance knowledge and 
awareness need to be concentrated on younger adolescents.  
 
Insufficient knowledge of HPV in adolescent boys may be reflective of many countries’ 
information campaigns being targeted to females only, with a clear focus on cervical cancer. 
This connotation that HPV is a women’s problem, and its subsequent impact on primary 
prevention efforts is referred to as the ‘feminisation of HPV’ [62]. This ‘feminisation’ is 
important as it impacts on how the general public, health care professionals and policy 
makers view HPV and HPV vaccination as a female only issue [62]. It is also possible that 
low male knowledge (compared to females) is due to males not being recommended or 
offered the HPV vaccine at time of data collection. This was not the case in the US; despite 
the vaccine being available for males at time of data collection; knowledge in adolescent 
males was still low. This could be reflective of how the vaccine is offered in the US via a 
health care practitioner and not offered through school-based programmes. This approach is 
leading to low vaccine uptake in the US, there is evidence to suggest that vaccine uptake in 
adolescent males is low; in 2012 only 20.8% of US boys aged 13 – 17 received at least one 
dose, and  only 6.8% receiving the full three dose schedule [63].  This can be contrasted 
with a school-based universal vaccination programme in the Canadian province of Prince 
Edward Island, where 79% of adolescent boys received all three doses of vaccination 
(although again male vaccination was significantly lower than females (85%; p=0.004)) [64]. 
Based on the prevailing evidence, what is needed is better health education and public 
information to maximise public awareness that HPV affects both men and women and 
should be of concern of both sexes. As illustrated by Hoglund et al. [50], it is possible that 
HPV vaccine marketing has only reached health care professionals and not the general 
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public and this may be why adolescent HPV knowledge is so low. Nevertheless, it is crucial 
that when HPV is marketed to the general public it is not presented as a vaccine for females, 
but as a universal vaccine for all [62].   
 
Although knowledge is low, it is important to note that knowledge was not always predictive 
of vaccine acceptance and uptake. In this review, the high quality studies indicated that 
knowledge was not predictive of willingness to be vaccinated or actual vaccine uptake. 
Parental and health care provider knowledge, acceptance and recommendation, though not 
specifically examined in this review, was seen as an important correlate of vaccine 
acceptance in adolescents [36,40,43]. There is an opportunity for education to extend 
beyond vaccination to HPV transmission and other prevention measures. As knowledge and 
acceptance are not always correlated, i.e. an adolescent may consider vaccination without 
adequate knowledge, health care professionals responsible for vaccination should use the 
opportunity to inform adolescents about HPV and its associated cancers. In research 
studies, we should not look at knowledge in isolation as it is not always predictive of uptake; 
in research of this nature; attitudes to vaccination may be more informative. Although there 
may be a discrepancy between vaccine intent and actual receipt of vaccination. The cross-
sectional nature of the research included in this review makes it difficult to determine if 
vaccine acceptance or intent to vaccinate leads to actual vaccine uptake.  
 
Few studies on vaccine acceptance in adolescent boys are guided by a theoretical 
framework around decision making or behaviour change, which makes the identification and 
exploration of factors that influence vaccine uptake difficult. In future research, a theoretical 
framework such as the Precaution Adoption Process Model (PAPM), a model of behaviour 
change with six stages of decision-making [65], may be beneficial for work of this nature. 
The PAPM categorises individuals as 1) unaware 2) unengaged, 3) undecided 4) decided 
not to act 5) decided to act 6) acting. This model applied in a longitudinal survey would allow 
for the crucial identification of factors that caused the change in health behaviour. The PAPM 
is suited to research in vaccine acceptance and uptake, as it identifies those who are aware 
of the vaccine but decided not to act. The categorisation of individuals who have decided to 
act and those individuals who have acted (i.e. received the vaccine) allows the crucial 
identification of factors that lead individuals to receive the vaccine. It is likely that a different 
intervention would be needed for individuals at different stages of the PAPM. For example, 
someone is stage 1 (unaware) may benefit most from awareness raising interventions in the 
media or from health care professionals; whereas someone who has decided to act may 
need assistance in accessing the vaccine.  
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Future research recommendations 
It is imperative that future research utilises consistent measures of HPV knowledge and 
attitudes to facilitate interpretation and comparison across studies internationally. One scale 
that could be used is that developed by Waller et al [66], which has demonstrated 
satisfactory psychometric properties and could be appropriately adapted for use to various 
other populations, for example, adolescents. Prospective longitudinal studies designed and 
informed by the PAPM as described above, would be more informative providing data on 
factors that influenced the move from vaccine intention to uptake.  In addition, more complex 
research designs to determine whether age or sexual activity impact on HPV and HPV 
vaccine knowledge would be beneficial.  
 
From a policy perspective, it is important to identify ways in which awareness among male 
adolescents can be increased, while also using an evidence based approach to support 
recommendations regarding universal HPV vaccination. More in depth analysis of the 
reasons for high awareness among male adolescents in countries such as Thailand may 
provide valuable insights that can have broader application. Data from countries/regions 
where HPV vaccination in males has been implemented can help inform policy decision 
making, and this data should include heath economic analysis concerning the cost 
effectiveness of a universal vaccination approach. Public awareness campaigns such as 
HPV Action’s “Jabs for the Boys” in the UK can also be effective, particularly if they are 
linked with effective lobbying of decision makers by coalitions of healthcare professionals 
and patient advocates   
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Figure 2 HPV and HPV vaccine knowledge grouped per Continent 
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Table 1: Included studies table  
Study Design Country 
and 
vaccine 
status** 
Sample  HPV 
vaccine 
status 
Setting HPV knowledge/HPV 
vaccine knowledge  
HPV acceptance (% boys 
vaccinated/willing to be 
vaccinated) 
Factors associated with 
acceptance.  
 Study 
quality  
Americas 
Bhatta 
2015 [36] 
C/S 
YRBSS 
USA; boys 
aged 9-26 
1299 (674 
boys, 625 
girls) 
11 – 18 years 
 
Rural 
Appalachian 
Ohio 
 
RR 69-82% 
 
11.5% 
boys 
have 
received 
1 dose 
hpv 
vaccine 
School Assessed knowledge of HPV 
vaccine only.  
 
42.1% boys knew about 
HPV vaccine.  
11.5% boys have received 1 
dose of HPV vaccine. 1.4% 
received all 3 doses.  
Not examined H 
**Moss 
2015 [37] 
And 
Reiter 
2011 [38] 
C/S 
Online 
SAQ 
USA;  412 boys 
11 – 17 years 
 
National 
sample; 2010 
HIS study 
 
RR 73% 
NK Online Assessed knowledge of HPV 
and knowledge of HPV 
vaccine. 
  
25% aware of HPV, 26% 
aware of vaccine, of these 
38% aware that boys can 
receive vaccine.  
28.9% were willing to be 
vaccinated.  
3.57 believed it was 
important to protect health 
(on 5 point scale). Perceived 
likelihood of getting HPV was 
2.02 (on 4 point scale). 
Anticipated regret of HPV 
infection was 3.14 (on 4 point 
scale).  
 
H 
Shao 
2015 [39] 
C/S 
SAQ 
2011 - 
2012 
USA; boys 
9 -26 
101 
Caribbean 
and AA boys  
range 13 - 19; 
53 (13-17); 48 
(18+).  
 
RR 79% 
NK Medical 
clinic 
Assessed knowledge of HPV 
and knowledge of HPV 
vaccine. 
 
65% knew what HPV was; 
27% knew HPV caused 
cervical cancer and rectal 
cancer in males. 45% heard 
of the vaccine.  
 
65% interested in receiving 
the vaccine  
 
Higher knowledge associated 
with greater acceptability. 
Condom use reduced interest 
in HPV vaccine; increase no of 
sexual partners increased 
interest in vaccine. Routine 
physical exam less likely to 
have an interest in vaccine; 
previous STI increased 
interest. 
L 
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Gutierrez 
2013 [40] 
 
 
C/S 
SAQ and 
FG 
USA; boys 
aged 9-26 
76 boys 
13 – 21 years 
 
Urban; Low 
income; 
Philadelphia 
 
RR ? 
UV Comm Assessed knowledge of HPV 
and knowledge of HPV 
vaccine. 
 
42% heard of HPV (77% 
MSM), 39% heard of 
vaccine 
 
[18% heterosexual heard of 
HPV; 77% MSM] 
 
50% said they would get 
vaccinated within the next 12 
months.  
 
Higher knowledge associated 
with greater acceptability. 
60% boys believe vaccination 
would be easy. 68% believe 
getting vaccinated is smart. 
64% believe vaccination is 
safe. 
 
 
 
 
L 
**Mayer 
2013 [41] 
 
C/S 
Online 
SAQ 
USA; boys 
9-26 
176 boys 
15 – 17 
years** 
 
National 
sample.  
 
RR 73% 
V and 
UV 
online Assessed knowledge of HPV 
only.  
 
40% heard of HPV; 15% 
heard of HPV, with low 
knowledge. 25% heard of 
HPV, high knowledge.  
Percentage willingness not 
assessed, although perceived 
likelihood of getting HPV was 
2.09 on a 4 point scale (1=no 
chance, 4=high chance) 
Perceived peer acceptance of 
vaccine was 3.06 on 5 point 
scale (1=strongly disagree, 
5=strongly agree), 
Anticipated regret if didn’t 
get HPV vaccine and later got 
HPV infection was 3.16 on 4 
point scale (1= nothing at all, 
5= a lot) 
 
H 
** Reiter et al., 2011; Moss et al., 2015 and Mayer et al., 2013 all report on data from the 2010 HPV Immunization in Sons (HIS) Study. Mayer used a subsample of boys aged 15 – 17 
years as their study focussed on sexual disinhibition, these items were not asked of younger sons.  
EUROPE 
Maier 
2015 [42] 
C/S 
SAQ 
Romania; 
no male 
vaccine 
524 (262 
boys, 262 
girls) 
16 – 18 years 
 
Two schools 
in Bucharest 
 
UV School Assessed knowledge of HPV 
and knowledge of HPV 
vaccine. 
 
17% boys heard of HPV; 8% 
boys heard of the vaccine. 
Significantly lower than 
girls.  
 
No significant difference in 
knowledge scores between 
boys and girls. Only 6.6% 
had high knowledge, 60% 
fair knowledge, 34% low 
knowledge.  
If they received more 
information on vaccination, 
43% of boys would be willing 
to be vaccinated.  
Lack of information M 
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Hilton 
2013 [43] 
 
C/S 
FG 
Scotland; 
no male 
vaccine 
59 (30 boys, 
29 girls) 
13 – 18 years 
 
Diverse 
sample 
UV Comm Assessed HPV knowledge 
via discussions on 
awareness of disease, and 
understanding of disease 
process and symptoms 
 
Boys demonstrated little 
awareness of HPV, believed 
it affected only females 
 
Not examined.  Viewed as a prevalent 
infection and a serious 
disease. 
 
Fear of needles and pain.  
 
Samkang
e-Zeeb 
2013 [44] 
C/S 
SAQ 
2011 
Germany ; 
no male 
vaccine 
1148  (632 
females and 
516 
Males) 
12-20 years 
old 
 
Bremen and 
Bremerhaven 
Northern 
Germany 
 
RR 28% 
UV School Assessed knowledge of HPV 
and knowledge of HPV 
vaccine. 
 
Significantly more females 
than males had heard of 
HPV (18 vs. 8 %) 
15% of boys aware that 
HPV causes cervical cancer; 
9% of boys aware of HPV 
vaccination.  
Not examined Not examined M 
Stocker 
2013 [45] 
C/S 
SAQ 
2010 
Germany; 
no male 
vaccine 
442 (238 girls, 
204 boys) 
13 – 19 years 
Berlin 
 
RR 59%  
60% 
girls V 
School  Assessed knowledge of HPV 
only. 
 
Boys showed same trend in 
knowledge as unvaccinated 
girls. Boys had less 
knowledge than vaccinated 
girls, but only slightly less 
than unvaccinated girls.  
43.9% knew HPV caused 
cervical cancer and penile 
cancer  
 
Not assessed in boys  Not assessed in boys M 
Forster 
2012 [46] 
C/S 
SAQ 
England; 
no male 
vaccine 
528 boys 
16 – 18 years 
 
One school SE 
UV School Assessed knowledge of HPV 
and knowledge of HPV 
vaccine. 
 
41% willing to receive 
vaccine. 
 
Boys who were unsure 
To protect health.  
Current sexual inactivity.  
M 
26 
 
England 
 
RR 89% 
52% boys aware of HPV whether to have the vaccine 
were signiﬁcantly less likely 
to have heard of HPV (44%) 
compared with boys who 
intended (63%) or did not 
intend (58%) to have it. 
 
Sopracor
devole 
2012 [47] 
 
 
C/S 
SAQ 
2009 
Italy; no 
male 
vaccine 
 
Third year 
of female 
vaccine 
1105 (476 
males, 629 
females) 
13 – 23 years 
(mean 15) 
 
One town NE 
Italy 
 
RR 100% 
45.4% 
girls 
vaccinat
ed 
School  Assessed knowledge of HPV 
and knowledge of HPV 
vaccine. 
 
51.3% boys heard of HPV 
(92.8% girls) better 
knowledge reported by 
girls.  Of those who were 
aware of HPV, more girls 
knew about the vaccine 
(94.5% v 71.3%) 
 
Not examined  Not examined  M 
Marek 
2011 [48] 
C/S 
SAQ 
Hungary; 
no male 
vaccine 
1769 (820 
boys, 949 
girls) 
12 – 19 years 
 
National 
sample 
 
RR 90% 
UV School Assessed knowledge of HPV 
and knowledge of HPV 
vaccine. 
 
20% primary school boys 
and 29% secondary school 
boys heard of HPV. Of 
those who had heard of 
HPV; 45% primary and 47% 
secondary boys know HPV 
linked to CC. 27% and 34% 
aware of link to genital 
warts. 
 
60% of boys would accept the 
vaccine if it was free.  
86% believed in the 
effectiveness of the vaccine.  
60% primary and 61% 
secondary boys would 
request vaccine if it was free. 
40% and 35% would pay for 
vaccine. 
Worries around side effects.  
H 
Pelucchi 
2010 [49] 
C/S 
SAQ 
2008 
Italy; no 
male 
vaccine  
 
First year 
of female 
vaccine 
M = 209; F = 
649 
14 – 20 years 
 
Milan, 
northern Italy 
 
UV School  Assessed knowledge of HPV 
and knowledge of HPV 
vaccine. 
 
Males had less knowledge 
of HPV (72 v 51%), thought 
it concerned them (only 
68% girls v 40% males said 
they would undergo 
vaccination. 
The students who were 
aware that HPV could affect 
them (felt at risk) were more 
in favour of vaccination 
regardless of whether or not 
they were M or F  
M 
27 
 
RR 79% 26% boys thought it did 
concern them versus 45% 
girls), the purpose of HPV 
vac (75 v 63% of those who 
had heard of HPV)  
 
Hoglund 
2009 [50] 
C/S 
SAQ 
Sweden; 
no male 
vaccine 
459 (209 
boys, 250 
girls) 
15 – 20 years 
 
One town 
 
RR 80% 
UV School Assessed knowledge of HPV 
and knowledge of HPV 
vaccine. 
 
5% of total participants had 
heard of HPV, 1% aware of 
vaccine, 2% aware that 
boys can contract HPV.  
No difference between 
boys and girls.  
Not examined Not examined M 
Gottvall 
2009 [51] 
C/S 
SAQ 
Sweden; 
no male 
vaccine 
608 (347 girls, 
261 boys 
15 – 16 years 
 
RR 86% 
UV School Assessed knowledge of HPV 
only  
 
Virus 9.6% (boys only) 
74.3% boys would like 
vaccine 
 
High acceptance despite low 
knowledge 
 
76.3% believe vaccine is 
effective 
 
Current sexual inactivity 
 
Knowledge that vaccine 
protected against GW 
increased acceptance 
 
H 
ASIA 
Hussain 
2014 [52] 
 
C/S 
SAQ and 
SSI 
India; no 
male 
vaccine 
2500 (1570 
girls, 930 
boys) 
 1033 12-18 
years 
 
Urban and 
rural 
 
RR 96% 
UV School/ 
Universi
ty 
Assessed knowledge of HPV 
and knowledge of HPV 
vaccine. 
 
Very low level of 
knowledge – 15% of total 
sample aware of cervical 
cancer. Of 930 males, 103 
knew HPV caused cancer 
(11%), and 63 knew of the 
vaccine (7%).  
Female knowledge 
significantly higher.  
29.7% boys would be willing 
to have vaccine 
"a negative response was 
documented with respect to 
implementation of 
vaccination 
programme in India due to 
adverse effects of vaccine 
related deaths recently" 
L 
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Tang 
2014 [53] 
 
C/S 
SAQ 
China; no 
male 
vaccine 
848 (452 girls, 
396 boys) 
14-18 years 
 
RR 94% 
UV School Assessed knowledge of HPV 
and knowledge of HPV 
vaccine. 
 
Virus 10%, vaccine 9.1%  
 
Gender difference in 
knowledge scores  
 
Not examined Not examined H 
Songthap 
2012 [54] 
C/S 
SAQ 
Thailand; 
no male 
vaccine 
 
644 (343 girls, 
301 boys).  
12-15 years 
 
Bangkok  
 
RR 80% 
UV School Assessed knowledge of HPV 
and knowledge of HPV 
vaccine. 
Vaccine  60.18% (boys only) 
80% boys had knowledge of 
HPV. No gender difference 
in scores.  
 
Willingness to get vaccine 
25.3% in favour, 52.4% 
unsure, 22.3% against 
Availability, education, 
efficacy 37.2% 
H 
OCEANIA 
Zou 2014 
[55] 
C/S 
SAQ 
2010 - 
2012 
Australia; 
female 
only at 
time of 
study  
[male 
vaccine 
2013] 
 
200 MSM 
16 – 20 years 
 
Melbourne  
 
RR?  
UV Comm 
and 
other  
Assessed knowledge of HPV 
and knowledge of HPV 
vaccine. 
 
High level of HPV 
knowledge  
 
High acceptance - If vaccine 
free, 86% willing to disclose 
their sexuality to receive the 
vaccine  
80% not willing to purchase 
the vaccine because of its 
cost.  
M 
Agius 
2010 [56] 
C/S 
SAQ 
2008 
Australia; 
Female 
vaccine at 
time of 
data 
collection 
1927 (793 
boys, 1134 
girls) 
14-20 years 
 
Nationally 
representative 
 
RR 66% 
 
UV School Assessed knowledge of HPV 
and knowledge of HPV 
vaccine. 
 
19.2% boys aware of virus 
 
8.5% boys aware of vaccine 
availability 
Not examined Not examined M 
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AFRICA 
Poole 
2013 [57] 
C/S 
SSI 2011 
Mali; no 
male 
vaccine. 
Prior to 
HPV 
vaccine 
licensing  
adolescents: 
20 (12 male) 
14 years  
 
Convenience 
sample 
 
RR 98% 
UV in own 
home 
Assessed knowledge of HPV 
 
Low levels of knowledge in 
both genders.  
100% said they’d be willing to 
receive the vaccine (despite 
low knowledge).  
Vaccine price  M 
 
C/S = cross-sectional; SAQ = self-administered questionnaire; YRBSS = The Youth Risk Behavior Surveillance System; V = vaccinated; UV = 
unvaccinated; RR = response rate; NK = not known; comm = community 
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Table 2: Critical Appraisal of quantitative/mixed methods studies 
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US 
Bhatta 2015  Y Y Y N Y N Y Y Y N H 
Moss 
2015/Mayer 
2013/ 
Reiter 2011 
Y Y Y N Y N Y Y Y N H 
Shao 2015 Y Y N Y N N Y CT Y N L 
Gutierrez 
2013 
Y Y N Y N N CT CT Y N L 
EUROPE 
Maier 2015 Y Y Y Y N N CT Y Y N M 
Stocker 
2013 
Y Y Y Y N Y Y Y Y N M 
Samkange-
Zeeb 2013 
Y Y Y N Y N N CT Y N M 
Forster 2012 Y Y Y Y N N Y CT Y N M 
Sopracordev
ole 2012 
Y Y Y Y N N Y Y Y N M 
Marek 2012 Y Y Y N Y N Y Y Y N H 
Pelucchi 
2010 
Y Y Y Y N N Y Y Y N M 
Hoglund 
2009 
Y Y Y N Y N Y CT Y N M 
Gottvall 
2009  
Y Y Y N N Y Y Y Y N H 
OCEANIA 
Zou 2014 Y Y Y Y N Y CT CT Y N M 
Agius 2010 Y Y Y N Y N Y N Y N M 
AFRICA 
31 
 
Poole 2013 Y Y Y Y N N Y N Y N M 
ASIA 
Hussain 
2014 
Y Y N CT N N Y CT Y N L 
Tang 2014 Y Y Y N Y Y Y Y Y N H 
Songthap 
2012 
Y Y Y N N Y Y Y Y N H 
Y = Yes N = No CT = Can’t tell  
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Table 3: Critical appraisal of qualitative studies 
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collecti
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Valuable? 
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on 
201
3 
Y Y Y Y 
Various 
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ent 
sources, 
purposi
ve 
samplin
g, 
diverse 
sample 
No 
mentio
n of 
data 
saturati
on, 
limited 
justific
ation 
for 
focus 
groups 
Not 
discuss
ed 
Not 
discus
sed  
Y Y Limited 
generalisa
bility.  
Gave 
suggestio
ns for 
future 
research. 
Y = Yes N = No CT = Can’t tell 
 
